HDAC inhibitor-based therapies: can we interpret the code?

HDAC inhibitor-based therapies: can we interpret the code?

Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...

書目詳細資料
Main Authors:	New, M, Olzscha, H, La Thangue, N
格式:	Journal article
語言:	English
出版:	2012

相似書籍

The TLR adaptor protein MyD88 mediates cell sensitivity to HDAC inhibitors through a cytokine-dependent mechanism
由: Sheikh, S, et al.
出版: (2016)

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
由: New, M, et al.
出版: (2013)

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
由: New, M, et al.
出版: (2013)

HDAC inhibitor-based therapies and haematological malignancy.
由: Stimson, L, et al.
出版: (2009)

TLR adaptor protein MYD88 mediates sensitivity to HDAC inhibitors via a cytokine-dependent mechanism
由: New, M, et al.
出版: (2016)

Biomarkers for predicting clinical responses to HDAC inhibitors.
由: Stimson, L, et al.
出版: (2009)

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
由: Khan, O, et al.
出版: (2012)

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
由: Khan, O, et al.
出版: (2010)

Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
由: Linda Anna Michelle Kulka, et al.
出版: (2020-06-01)

Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
由: New, M
出版: (2014)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
由: Liu, G, et al.
出版: (2023)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
由: Wiktoria Blaszczak, et al.
出版: (2021-12-01)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
由: Geng Liu, et al.
出版: (2023-01-01)

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
由: Fotheringham, S, et al.
出版: (2009)

Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy
由: Miranda E Clements, et al.
出版: (2023-03-01)

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
由: Khan, O, et al.
出版: (2008)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
由: Cristina Maccallini, et al.
出版: (2022-05-01)

CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation
由: Olzscha, H, et al.
出版: (2016)

Bromodomains control amyloid-like aggregation of aberrantly acetylated proteins
由: Olzscha, H, et al.
出版: (2018)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
由: Jacob King, et al.
出版: (2021-11-01)

Can We Interpret Implicitness?
由: Dilem Dinc, et al.
出版: (2023-12-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
由: Elizabeth A. Thomas
出版: (2014-05-01)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
由: Zsófia Kutil, et al.
出版: (2019-11-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
由: Wanli Zhang, et al.
出版: (2025-02-01)

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition
由: Jing Zhou, et al.
出版: (2023-07-01)

The efficacy of HDAC inhibitors in neoplasm treatment
由: Dominika Psiuk, et al.
出版: (2020-08-01)

Current HDAC Inhibitors in Clinical Trials
由: Elisabetta Di Bello, et al.
出版: (2022-05-01)

The Effect of Quisinostat as the HDAC Inhibitor on Migration
由: Marjan Hajimoradi Javarsiani, et al.
出版: (2021-08-01)

The Effect of Quisinostat as the HDAC Inhibitor on Migration
由: Marjan Hajimoradi Javarsiani, et al.
出版: (2021-08-01)

Phosphorus containing analogues of SAHA as inhibitors of HDACs
由: Michael D. Pun, et al.
出版: (2022-12-01)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
由: Sophia G Liva, et al.
出版: (2020-01-01)

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice
由: Alessandra Tammaro, et al.
出版: (2024-01-01)

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
由: Lourdes Hontecillas-Prieto, et al.
出版: (2020-09-01)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
由: Mohamed D. M. Traoré, et al.
出版: (2017-04-01)

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S. mansoni larval and adult worm stages.
由: Roberto Gimmelli, et al.
出版: (2024-02-01)

HDAC Inhibitors: Innovative Strategies for Their Design and Applications
由: Mateusz Daśko, et al.
出版: (2022-01-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
由: Ehab Ghazy, et al.
出版: (2022-01-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
由: Laurence Booth, et al.
出版: (2019-07-01)

Diversity within the pRb pathway: is there a code of conduct?
由: Munro, S, et al.
出版: (2012)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
由: Beatriz Silva Urias, et al.
出版: (2022-10-01)